Oxaliplatine Accord

Oxaliplatin, the active ingredient in Oxaliplatine Accord, is a platinum compound presented as an injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, including adjuvant therapy for stage III colon cancer and metastatic disease. It is approved for use in the European Union and is administered under the supervision of oncology specialists.

GNH USA supplies Oxaliplatine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across global markets.

Oxaliplatin is a platinum‑based chemotherapy agent that interferes with DNA replication and is incorporated into standard regimens for colorectal cancer management. Its inclusion in multi‑drug protocols has become a cornerstone of modern colorectal oncology, offering a balance of efficacy and manageable toxicity when administered by trained professionals. - Colorectal cancer: combined with fluoropyrimidine and leucovorin, it helps shrink primary tumors and improve resection rates. - Adjuvant therapy for stage III colon cancer: given after surgical resection to reduce the risk of disease recurrence. - Metastatic colorectal cancer: used in combination protocols to control tumor spread and extend overall survival.

Oxaliplatin may cause a range of adverse reactions, varying from mild to severe, that are monitored throughout therapy.

Common Side Effects: - Nausea: mild to moderate episodes often managed with antiemetics. - Peripheral neuropathy: tingling or numbness in extremities, may be cumulative. - Fatigue: general tiredness affecting daily activities. - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: decreased red blood cells leading to fatigue and pallor. - Vomiting: occasional episodes, may require supportive care.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis requiring immediate medical intervention. - Pulmonary toxicity: interstitial lung disease presenting with cough and dyspnea. - Thrombocytopenia: markedly low platelet count causing bleeding tendencies. - Cardiac arrhythmia: irregular heart rhythm observed in rare cases. - Tumor lysis syndrome: rapid tumor cell breakdown leading to metabolic disturbances.

Prior to initiating oxaliplatin therapy, clinicians should evaluate patient-specific factors and implement monitoring strategies to mitigate risks. - Renal function: assess baseline creatinine clearance and monitor during treatment. - Hepatic function: evaluate liver enzymes before each cycle. - Peripheral neuropathy: conduct neurological assessment prior to dosing and adjust if symptoms progress. - Pregnancy: avoid use; category unknown and potential fetal harm. - Drug interactions: review concomitant medications for nephrotoxic or neurotoxic agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oxaliplatin can interact with other medicines, influencing its efficacy or toxicity profile.

Major Interactions (Avoid): - Cisplatin: concurrent use increases risk of cumulative nephrotoxicity and neurotoxicity. - Nephrotoxic antibiotics (e.g., aminoglycosides): may exacerbate renal impairment. - Live vaccines: contraindicated during immunosuppressive chemotherapy.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may require dose adjustment to control nausea. - Calcium and magnesium infusions: can reduce oxaliplatin‑induced neuropathy, monitor electrolyte balance. - Warfarin: monitor INR as oxaliplatin may affect anticoagulant control.